CANDEL THERAPEUTICS, INC. Operating Expenses
CANDEL THERAPEUTICS, INC. (CADL) reported Operating Expenses of $26.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $26.75M, a 139.29% increase year-over-year.
- CANDEL THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $16.28M, a 100.30% increase year-over-year.
- CANDEL THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $15.75M, a 93.49% increase year-over-year.
- CANDEL THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $13.21M, a 50.82% increase year-over-year.
- CANDEL THERAPEUTICS, INC. operating expenses for fiscal 2025 was $48.27M, a 44.63% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. operating expenses for fiscal 2024 was $33.37M, a 13.08% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. operating expenses for fiscal 2023 was $38.39M, a 10.17% increase from fiscal 2022.
- CANDEL THERAPEUTICS, INC. operating expenses for fiscal 2022 was $34.85M, a 34.80% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.75M 10-Q · filed 2026-08-13 | $43.03M 10-Q · filed 2026-08-13 | $58.78M derived: sum of 3 quarters · filed 2026-08-13 | $71.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $16.28M 10-Q · filed 2026-05-14 | $32.04M derived: sum of 2 quarters · filed 2026-05-14 | $45.24M derived: sum of 3 quarters · filed 2026-05-14 | $56.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $28.96M derived: sum of 2 quarters · filed 2026-03-12 | $40.14M derived: sum of 3 quarters · filed 2026-08-13 | $48.27M 10-K · filed 2026-03-12 |
| 2025-09-30 | $13.21M 10-Q · filed 2025-11-13 | $24.38M derived: sum of 2 quarters · filed 2026-08-13 | $32.51M 10-Q · filed 2025-11-13 | $40.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $11.18M 10-Q · filed 2026-08-13 | $19.31M 10-Q · filed 2026-08-13 | $27.45M derived: sum of 3 quarters · filed 2026-08-13 | $36.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $8.13M 10-Q · filed 2026-05-14 | $16.27M derived: sum of 2 quarters · filed 2026-05-14 | $25.03M derived: sum of 3 quarters · filed 2026-05-14 | $33.60M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $16.90M derived: sum of 2 quarters · filed 2026-03-12 | $25.47M derived: sum of 3 quarters · filed 2026-03-12 | $33.37M 10-K · filed 2026-03-12 |
| 2024-09-30 | $8.76M 10-Q · filed 2025-11-13 | $17.33M derived: sum of 2 quarters · filed 2025-11-13 | $25.23M 10-Q · filed 2025-11-13 | $35.55M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $8.57M 10-Q · filed 2025-08-14 | $16.47M 10-Q · filed 2025-08-14 | $26.79M derived: sum of 3 quarters · filed 2025-08-14 | $35.65M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $7.90M 10-Q · filed 2025-05-13 | $18.22M derived: sum of 2 quarters · filed 2025-05-13 | $27.08M derived: sum of 3 quarters · filed 2025-05-13 | $36.66M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $10.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $19.18M derived: sum of 2 quarters · filed 2025-03-13 | $28.76M derived: sum of 3 quarters · filed 2025-03-13 | $38.39M 10-K · filed 2025-03-13 |
| 2023-09-30 | $8.86M 10-Q · filed 2024-11-14 | $18.44M derived: sum of 2 quarters · filed 2024-11-14 | $28.07M 10-Q · filed 2024-11-14 | $36.20M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $9.58M 10-Q · filed 2024-08-13 | $19.21M 10-Q · filed 2024-08-13 | $27.34M derived: sum of 3 quarters · filed 2024-08-13 | $36.26M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $9.63M 10-Q · filed 2024-05-14 | $17.77M derived: sum of 2 quarters · filed 2024-05-14 | $26.68M derived: sum of 3 quarters · filed 2024-05-14 | $35.46M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $17.04M derived: sum of 2 quarters · filed 2024-03-28 | $25.83M derived: sum of 3 quarters · filed 2024-03-28 | $34.85M 10-K · filed 2024-03-28 |
| 2022-09-30 | $8.91M 10-Q · filed 2023-11-09 | $17.70M derived: sum of 2 quarters · filed 2023-11-09 | $26.71M 10-Q · filed 2023-11-09 | $34.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $8.78M 10-Q · filed 2023-08-10 | $17.80M 10-Q · filed 2023-08-10 | $25.57M derived: sum of 3 quarters · filed 2023-08-10 | $33.63M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $9.02M 10-Q · filed 2023-05-11 | $16.79M derived: sum of 2 quarters · filed 2023-05-11 | $24.85M derived: sum of 3 quarters · filed 2023-05-11 | $30.18M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $15.83M derived: sum of 2 quarters · filed 2023-03-30 | $21.16M derived: sum of 3 quarters · filed 2023-03-30 | $25.85M 10-K · filed 2023-03-30 |
| 2021-09-30 | $8.06M 10-Q · filed 2022-11-10 | $13.39M derived: sum of 2 quarters · filed 2022-11-10 | $18.08M 10-Q · filed 2022-11-10 | $24.24M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.33M 10-Q · filed 2022-08-05 | $10.02M 10-Q · filed 2022-08-05 | $16.18M derived: sum of 3 quarters · filed 2022-08-05 | $18.96M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $4.69M 10-Q · filed 2022-05-12 | $10.84M derived: sum of 2 quarters · filed 2022-05-12 | $13.62M derived: sum of 3 quarters · filed 2022-05-12 | $16.27M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $8.94M derived: sum of 2 quarters · filed 2022-03-29 | $11.59M derived: sum of 3 quarters · filed 2022-03-29 | $13.94M 10-K · filed 2022-03-29 |
| 2020-09-30 | $2.78M 10-Q · filed 2021-11-12 | $5.43M derived: sum of 2 quarters · filed 2021-11-12 | $7.78M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.65M 10-Q · filed 2021-09-08 | $5.00M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |